Maker of popular diabetes and weight-loss drugs grilled about high cost in the U.S.

The CEO of Novo Nordisk was questioned about the high cost in the U.S. of Wegovy and Ozempic, the wildly popular diabetes and weight-loss drugs. Lars Jorgensen said pharmacy benefit managers are mostly to blame. NBC News' Stephanie Gosk reports. » Subscribe to NBC News: http://nbcnews.to/SubscribeToNBC » Watch more NBC video: http://bit.ly/MoreNBCNews NBC News Digital is a collection of innovative and powerful news brands that deliver compelling, diverse and engaging news stories. NBC News Digital features NBCNews.com, MSNBC.com, TODAY.com, Nightly News, Meet the Press, Dateline, and the existing apps and digital extensions of these respective properties. We deliver the best in breaking news, live video coverage, original journalism and segments from your favorite NBC News Shows. Connect with NBC News Online! NBC News App: https://apps.nbcnews.com/mobile Breaking News Alerts: https://link.nbcnews.com/join/5cj/breaking-news-signup?cid=sm_npd_nn_yt_bn-clip_190621 Visit NBCNews.Com: http://nbcnews.to/ReadNBC Find NBC News on Facebook: http://nbcnews.to/LikeNBC Follow NBC News on Twitter: http://nbcnews.to/FollowNBC Follow NBC News on Instagram: http://nbcnews.to/InstaNBC #WeightLoss #Wegovy #Ozempic